Cascadian Therapeutics
Nov 8, 2017

Cascadian Therapeutics Reports Third Quarter 2017 Financial Results

Conference Call Scheduled for Today at 4:30 p.m. ET

SEATTLE, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2017, and provided an update on tucatinib, an investigational oral, small molecule kinase inhibitor that is highly selective for HER2 and the Company's lead product in development for the treatment of HER2 overexpressing cancers.

Scott Myers, President and CEO of Cascadian Therapeutics, stated, "We had a productive third quarter. Tucatinib was granted orphan drug designation for a second indication, HER2+ colorectal cancer and enrollment began for an investigator-sponsored study of tucatinib in combination with trastuzumab in HER2 amplified metastatic colorectal cancer. Results from a pooled analysis of tucatinib combination studies were presented at ESMO that provide further support for the development of tucatinib in HER2+ metastatic breast cancer with brain metastases. Finally, enrollment of the HER2CLIMB pivotal trial continues to be robust, and we expect to end the year within our cash guidance."

Mr. Myers added, "We look forward to sharing new follow up data from our tucatinib Phase 1b studies at the San Antonio Breast Cancer Symposium in early December."

Third Quarter and Recent Highlights

Third Quarter Financial Results

2017 Financial Outlook

Cascadian Therapeutics expects operating expenses in 2017 to be slightly higher than in 2016, primarily due to an increase in activities related to the ongoing worldwide HER2CLIMB pivotal trial. Cash used in operations for 2017 is expected to be approximately $50.0 million to $54.0 million.

Cascadian Therapeutics believes the above financial guidance to be correct as of the date hereof and is providing the guidance as a convenience to investors and assumes no obligation to update it.

Conference Call Information

Cascadian Therapeutics management will host a conference call and live audio webcast to review its third quarter financial results and provide an update on business activities today at 4:30 p.m. ET / 1:30 p.m. PT. Participants can access the call at +1 (877) 280-7291 (domestic) or +1 (707) 287-9361 (international). To access the live audio webcast or the subsequent archived recording, visit the Events & Presentations page of the News & Events section of the Cascadian Therapeutics' website at

About Cascadian Therapeutics

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib, is an investigational oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind, controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab, in patients with locally advanced or metastatic HER2+ breast cancer with and without brain metastases, who have previously been treated with trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at or For more information, please visit

Forward-Looking Statements

In order to provide Cascadian Therapeutics' investors with an understanding of its current results and future prospects, this release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include Cascadian Therapeutics' expectations regarding clinical development activities, HER2CLIMB enrollment, timing of additional data, potential benefits of its product candidates, timing of submission of marketing applications, potential regulatory approvals, and its use and adequacy of cash reserves and future financial results.

Forward-looking statements involve risks and uncertainties related to Cascadian Therapeutics' business and the general economic environment, many of which are beyond its control. These risks, uncertainties and other factors could cause Cascadian Therapeutics' actual results to differ materially from those projected in forward-looking statements, including the risks associated with the costs and expenses of developing its product candidates, the adequacy of financing and cash, cash equivalents and investments, changes in general accounting policies, general economic factors, achievement of the results it anticipates from its preclinical development and clinical trials of its product candidates, the receipt of regulatory approvals, and its ability to adequately obtain and protect its intellectual property rights. Although Cascadian Therapeutics believes that the forward-looking statements contained herein are reasonable as of the date hereof, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of Cascadian Therapeutics' risks and uncertainties, you should review the documents filed by Cascadian Therapeutics with the securities regulators in the United States on EDGAR and in Canada on SEDAR. Cascadian Therapeutics does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by law.

Additional Information

Additional information relating to Cascadian Therapeutics can be found on EDGAR at and on SEDAR at

Investor and Media Contact:
Monique Greer
Cascadian Therapeutics

Condensed Consolidated Statements of Operations
(In thousands except share and per share amounts)
 Three months ended
September 30,

  Nine months ended
September 30,

 2017 2016
Operating expenses                 
Research and development$   10,910  $  7,281  $   31,011  $  19,998 
General and administrative   3,448     3,511     9,930     14,509 
Intangible asset impairment    —     —     —     19,738 
Total operating expenses    14,358      10,792     40,941     54,245 
Loss from operations   (14,358)    (10,792)      (40,941)    (54,245)
Other income                 
Investment and other income, net   297     19     769     144 
Total other income, net   297     19     769     144 
Net loss before income taxes$   (14,061) $  (10,773) $   (40,172) $    (54,101)
Income tax benefit   —     —     —     (6,908)
Net loss    (14,061)    (10,773)    (40,172)    (47,193)
Deemed dividend related to beneficial conversion feature on convertible preferred stock   —     (989)    (982)    (2,588)
Net loss attributable to common stockholders   (14,061)    (11,762)    (41,154)    (49,781)
Net loss per share — basic and diluted$  (0.28) $  (0.52) $   (0.87) $   (2.74)
Shares used to compute basic and diluted net loss per share   50,404,201     22,551,740      47,089,996     18,159,603 

Consolidated Balance Sheet Data
(In thousands except share amounts)
    As of
   September 30, 2017 December 31, 2016
Cash, cash equivalents and investments $112,979 $62,805
Total assets  $133,387 $83,265
Long term liabilities $38 $135
Stockholders' equity $124,616 $74,357
Common shares outstanding  50,560,320  22,562,640